The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Roche
Travel, Accommodations, Expenses - Abbvie
Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
 
William G. Wierda
Consulting or Advisory Role - Abbvie; Celgene; Emergent BioSolutions; Genentech/Roche; Genzyme; Gilead Sciences; GlaxoSmithKline/Novartis; Merck; Pharmacyclics; Sanofi
Research Funding - Abbvie; Acerta Pharma; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics
 
Tanya Siddiqi
Consulting or Advisory Role - Juno Therapeutics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics; Kite, a Gilead company
 
Ian Flinn
Stock and Other Ownership Interests - RainTree Oncology Services
Research Funding - Acerta Pharma (Inst); Agios (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunogen (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)
 
Xavier C. Badoux
No Relationships to Disclose
 
Thomas J. Kipps
Consulting or Advisory Role - Abbvie; Genentech; Gilead Sciences; Pharmacyclics
Research Funding - Abbvie; Genentech; Oncternal Therapeutics; Pharmacyclics
 
John N. Allan
Consulting or Advisory Role - Abbvie; Astellas Pharma; Genentech; Pharmacyclics; Verastem
Speakers' Bureau - Abbvie; Genentech; Pharmacyclics
 
Alessandra Tedeschi
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche
Consulting or Advisory Role - Abbvie; Janssen
 
John M. Pagel
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics
 
Bryone J. Kuss
Honoraria - Gilead Sciences; Janssen; Roche
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen; Merck; Mundipharma; Roche; Takeda
Speakers' Bureau - Gilead Sciences; Johnson & Johnson; Roche
 
Eva González Barca
Consulting or Advisory Role - Janssen; Roche
Speakers' Bureau - Gilead Sciences; Janssen; Roche
 
Paolo Ghia
Consulting or Advisory Role - AbbVie; Adaptive Biotechnologies; Gilead Sciences; Janssen; Pharmacyclics; Roche
Speakers' Bureau - Gilead Sciences
Research Funding - AbbVie; Gilead Sciences; Janssen; Novartis
 
Karl Eckert
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
Patents, Royalties, Other Intellectual Property - Pharmacyclics
Travel, Accommodations, Expenses - Pharmacyclics
 
Cathy Zhou
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
Joi Ninomoto
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie; Amgen; Celgene
 
James P. Dean
Employment - CTI; Pharmacyclics
Stock and Other Ownership Interests - Abbvie; CTI
 
Danelle Frances James
Employment - Abbvie/Pharmacyclics; Abbvie/Pharmacyclics (I)
Stock and Other Ownership Interests - Abbvie; Abbvie (I)
Patents, Royalties, Other Intellectual Property - Abbvie
 
Constantine Tam
Honoraria - Janssen
Consulting or Advisory Role - Janssen
Research Funding - Janssen